Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Rosetta Genomics nets $26.2mm through IPO on Nasdaq

16 Oct 2007

Executive Summary

Rosetta Genomics, which uses micro-ribonucleic acid (miRNA) to treat and diagnose diseases, netted $26.2mm (including the overallotment) in its initial public offering on Nasdaq of 4.3mm ordinary shares at $7 each, slightly below its planned price range of $7.50-8.50. In September 2006, the company announced its intention to sell 3mm shares at $11-13 apiece.
Deal Industry
  • In Vitro Diagnostics
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By